Theranostics in immuno-oncology using nanobody derivatives

Targeted therapy and immunotherapy have become mainstream in cancer treatment. However, only patient subsets benefit from these expensive therapies, and often responses are short‐lived or coincide with side effects. A growing modality in precision oncology is the development of theranostics, as this...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Theranostics
Autores principales: Lecocq, Quentin, De Vlaeminck, Yannick, Hanssens, Heleen, D'Huyvetter, Matthias, Raes, Geert, Goyvaerts, Cleo, Keyaerts, Marleen, Devoogdt, Nick, Breckpot, Karine
Formato: Artigo
Lenguaje:Inglês
Publicado: Ivyspring International Publisher 2019
Materias:
Review
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6831473/
https://ncbi.nlm.nih.gov/pubmed/31695800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.34941
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares